Key secondary outcomes concluded that PAR-1 antagonists were significantly associated with a lower risk of recurrent MI; (RR, 0.78; 95% CI, 0.67–0.92; p = 0.003) but greater incidence of TIMI major bleeding; RR 1.46 (95% CI, 1.29, 1.65, p < 0.0001) [32]. The gene discussed is F2R; the disease is myocardial infarction.